Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
AD-214's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for AD-214. Showing past 6 months and next 12 months · 10 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| AD-214 | Adalta | Fc Fusion Protein | Phase 1 | 0 | ||||
| Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole | Norfolk and Norwich University Hospitals NHS Foundation Trust | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis | Fondation Hôpital Saint-Joseph | — | Phase 3 | — | — | — | — | — |
| Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease | United Therapeutics | — | Phase 3 | — | — | — | — | — |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | Bristol-Myers Squibb | — | Phase 3 | — | — | — | — | — |
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | Boehringer Ingelheim | — | Phase 3 | — | — | — | — | — |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis | Haisco Pharmaceutical Group Co., Ltd. | — | Phase 3 | — | — | — | — | — |
| Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis | Argyrios Tzouvelekis | — | Phase 3 | — | — | — | — | — |
| Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis | University of Massachusetts, Worcester | — | Phase 3 | — | — | — | — | — |
| Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) | PureTech | — | Phase 3 | — | — | — | — | — |
| A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) | Beijing Tide Pharmaceutical Co., Ltd | — | Phase 3 | — | — | — | — | — |
| Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis | Bristol-Myers Squibb | — | Phase 3 | — | — | — | — | — |
| Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF | Sunshine Lake Pharma Co., Ltd. | — | Phase 3 | — | — | — | — | — |
| Anlotinib Capsules in the Treatment for IPF/PF-ILDs | First Affiliated Hospital of Wenzhou Medical University | — | PHASE2/PHASE3 | — | — | — | — | — |
| SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | Guangzhou JOYO Pharma Co., Ltd | — | PHASE2/PHASE3 | — | — | — | — | — |
| Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis | Redx Pharma Ltd | — | Phase 2 | — | — | — | — | — |
| LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | PureTech | — | Phase 2 | — | — | — | — | — |
| Genentech Xenon MRI Idiopathic Pulmonary Fibrosis | Duke University | — | Phase 2 | — | — | — | — | — |
| Phase ll Study of HEC585 in Patients With IPF | Sunshine Lake Pharma Co., Ltd. | — | Phase 2 | — | — | — | — | — |
| Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF) | Melius Pharma AB | — | Phase 2 | — | — | — | — | — |
| Xenon MRI and Progressive ILD | Duke University | — | Phase 2 | — | — | — | — | — |
| Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis | InSilico Medicine Hong Kong Limited | — | Phase 2 | — | — | — | — | — |
| Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis | Haisco Pharmaceutical Group Co., Ltd. | — | Phase 2 | — | — | — | — | — |
| SB17170 Phase 2 Trial in IPF Patients | SPARK Biopharma | — | Phase 2 | — | — | — | — | — |
| A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood | Boehringer Ingelheim | — | Phase 2 | — | — | — | — | — |
| MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Syndax Pharmaceuticals | — | Phase 2 | — | — | — | — | — |
| A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) | Endeavor Biomedicines, Inc. | — | Phase 2 | — | — | — | — | — |
| Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF | Daewoong Pharmaceutical Co. LTD. | — | Phase 2 | — | — | — | — | — |
| Long-term Safety and Efficacy Study of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Haisco Pharmaceutical Group Co., Ltd. | — | Phase 2 | — | — | — | — | — |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Reunion Neuroscience Inc | — | Phase 2 | — | — | — | — | — |
| AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | Avalyn Pharma Inc. | — | Phase 2 | — | — | — | — | — |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis | Shanghai Synvida Biotechnology Co.,Ltd. | — | Phase 2 | — | — | — | — | — |
| Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Cumberland Pharmaceuticals | — | Phase 2 | — | — | — | — | — |
| Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis | Cedars-Sinai Medical Center | — | Phase 2 | — | — | — | — | — |
| Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases | Erasme University Hospital | — | Phase 2 | — | — | — | — | — |
| A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | Boehringer Ingelheim | — | Phase 2 | — | — | — | — | — |
| A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | Vicore Pharma AB | — | Phase 2 | — | — | — | — | — |
| A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | Calluna Pharma AS | — | Phase 2 | — | — | — | — | — |
| WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Mediar Therapeutics | — | Phase 2 | — | — | — | — | — |
| A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | Rein Therapeutics | — | Phase 2 | — | — | — | — | — |
| H01 in Adults With Interstitial Lung Disease (The SOLIS Study) | National Institute of Environmental Health Sciences (NIEHS) | — | Phase 2 | — | — | — | — | — |
| A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis | Chiesi Farmaceutici S.p.A. | — | Phase 2 | — | — | — | — | — |
| Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis | Contineum Therapeutics | — | Phase 2 | — | — | — | — | — |
| Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis | Ruijin Hospital | — | Phase 2 | — | — | — | — | — |
| Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease | Vejle Hospital | — | Phase 2 | — | — | — | — | — |
| Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis | Dragonboat Biopharmaceutical Company Limited | — | Phase 2 | — | — | — | — | — |
| Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis | AbbVie | — | Phase 2 | — | — | — | — | — |
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) | Avalyn Pharma Inc. | — | Phase 2 | — | — | — | — | — |
| Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis | National Jewish Health | — | PHASE1/PHASE2 | — | — | — | — | — |
| Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure | Paul Szabolcs | — | PHASE1/PHASE2 | — | — | — | — | — |